| NCT05322330 |
II |
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-Cell Non-Hodgkin's Lymphoma |
CAR T
selinexor |
R/R B-cell NHL |
| NCT05202782 |
II |
Zanubrutinib and CAR T-Cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma or Transformed Indolent B-Cell Lymphoma |
CAR T
zanubrutinib |
R/R B-cell NHL |
| NCT05385263 |
II |
Addition of Nivolumab to Anti-CD19 CAR-T Cells in Patients with Stable/Progressive DLBCL at Lymphodepletion |
CAR T
nivolumab |
DLBCL |
| NCT04257578 |
I/II |
Acalabrutinib and Anti-CD19 CAR T-Cell Therapy for the Treatment of B-Cell Lymphoma |
axi-cel
acalabrutinib |
BCL |
| NCT05371093 (ZUMA-22) |
III |
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants with Relapsed/Refractory Follicular Lymphoma |
axi-cel
SoC |
R/R FL |
| NCT05459571 (ZUMA-24) |
II |
Study of Axicabtagene Ciloleucel Given with Steroids in Participants with Relapsed or Refractory Large B-Cell Lymphoma |
axi-cel
dexamethasone |
R/R LBCL |
| NCT02926833 (ZUMA-6) |
I/II |
Safety and Efficacy of KTE-C19 in Combination with Atezolizumab in Adults with Refractory Diffuse Large B-Cell Lymphoma |
axi-cel
atezolizumab |
R/R DLBCL |
| NCT04234061 (TARMAC) |
II |
Clinical Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma |
tisa-cel
ibrutinib |
R/R MCL |
| NCT03744676 (TRANSCEND-OUTREACH-007) |
II |
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma in the Outpatient Setting |
liso-cel |
R/R B-cell NHL |
| NCT04245839 (TRANSCEND FL) |
II |
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (TRANSCEND FL) |
liso-cel |
R/R B-cell indolent NHL |
| NCT03310619 (PLATFORM) |
I/II |
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies |
liso-cel
durvalumab
CC-122
ibrutinib
CC-220
relatlimab
nivolumab
CC-99282 |
FL, NHL, DLBCL |
| NCT02625480 (ZUMA-4) |
II |
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4) |
brexu-cel |
R/R B-ALL
R/R B-cell NHL |